Form 4: McKesson Corp EVP & CFO Britt J. Vitalone Reports Stock Transactions

Britt J. Vitalone, EVP & CFO of McKesson Corp, reports the sale and acquisition of common stock and vesting of Restricted Stock Units (RSUs) on May 23, 2024.

Summary

• On May 23, 2024, Britt J. Vitalone, the EVP & CFO of McKesson Corp, engaged in multiple transactions involving the company's stock.
• Vitalone sold 12,752 shares of common stock at a price of $558.09 per share under a pre-arranged Rule 10b5-1(c) trading plan.
• He also acquired 1,475 shares through the vesting of Restricted Stock Units (RSUs).
• 581 shares were withheld to cover taxes related to the RSU vesting at a price of $558.03.
• Following these transactions, Vitalone directly owns 14,922.377 shares of McKesson Corp common stock.
• Additionally, Vitalone indirectly owns 548.4599 shares through the McKesson Corporation 401(k) Retirement Savings Plan.
• The RSUs vest in three equal installments on May 23, 2024, May 23, 2025, and May 23, 2026.

Sentiment

Score: 6

Explanation: Neutral sentiment. The transactions are routine and part of a pre-arranged trading plan and compensation structure. The sale is offset by RSU vesting.

Positives

• The vesting of RSUs indicates a form of compensation and alignment with the company's long-term performance.

Negatives

• The sale of 12,752 shares, while under a pre-arranged plan, could be interpreted negatively by some investors if not properly understood in context.

Risks

• The market may react to the sale of shares, even if it's part of a pre-planned strategy.
• Changes in tax laws could affect the value and vesting schedule of RSUs.

Future Outlook

The remaining RSUs will vest in two tranches on May 23, 2025, and May 23, 2026.

Industry Context

Executive stock transactions are common and closely monitored in the pharmaceutical distribution industry. Investors often analyze these filings to gauge management's sentiment and alignment with company performance.

Comparison to Industry Standards

• Executive compensation packages in the pharmaceutical distribution industry often include RSUs to incentivize long-term performance, similar to McKesson's approach.
• Competitors like Cardinal Health and AmerisourceBergen also utilize similar equity-based compensation strategies for their executives.
• The vesting schedules and trading plans are generally in line with industry best practices for executive compensation and compliance.

Stakeholder Impact

• Shareholders may be interested in the details of executive compensation and stock transactions.
• Employees who participate in the 401(k) plan may be indirectly affected by the stock's performance.

Next Steps

• Monitor future Form 4 filings for any further transactions by Vitalone or other McKesson executives.
• Track the vesting of the remaining RSUs in 2025 and 2026.

Key Dates